NSPR vs. NPCE, DCTH, SKIN, CVRX, CLPT, GUTS, ARAY, TLSI, HSAQ, and QIPT
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include NeuroPace (NPCE), Delcath Systems (DCTH), Beauty Health (SKIN), CVRx (CVRX), ClearPoint Neuro (CLPT), Fractyl Health (GUTS), Accuray (ARAY), TriSalus Life Sciences (TLSI), Health Sciences Acquisitions Co. 2 (HSAQ), and Quipt Home Medical (QIPT). These companies are all part of the "surgical & medical instruments" industry.
InspireMD (NYSE:NSPR) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.
InspireMD presently has a consensus target price of $4.85, suggesting a potential upside of 43.07%. NeuroPace has a consensus target price of $14.83, suggesting a potential upside of 86.35%. Given NeuroPace's higher possible upside, analysts plainly believe NeuroPace is more favorable than InspireMD.
InspireMD has higher earnings, but lower revenue than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
In the previous week, NeuroPace had 2 more articles in the media than InspireMD. MarketBeat recorded 4 mentions for NeuroPace and 2 mentions for InspireMD. NeuroPace's average media sentiment score of 0.38 beat InspireMD's score of 0.00 indicating that NeuroPace is being referred to more favorably in the news media.
NeuroPace has a net margin of -45.61% compared to InspireMD's net margin of -350.35%. InspireMD's return on equity of -55.12% beat NeuroPace's return on equity.
NeuroPace received 22 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 54.55% of users gave NeuroPace an outperform vote while only 3.28% of users gave InspireMD an outperform vote.
InspireMD has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
44.8% of InspireMD shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 29.7% of InspireMD shares are held by company insiders. Comparatively, 22.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
NeuroPace beats InspireMD on 11 of the 18 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
